Related Experiment Video
Updated: May 5, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Older patients/older donors: choosing wisely
11Division of Hematology-Oncology, The University of Chicago Medicine, Chicago, IL.
Insights
Hematopoietic cell transplantation (HCT) in older adults can offer long-term survival, but careful patient selection and donor choice are crucial. Older sibling donors are often preferred, but matched unrelated donors also provide acceptable outcomes.
Area of Science:
- Geriatric Medicine
- Hematology
- Transplantation Immunology
Background:
- Allogeneic hematopoietic cell transplantation (HCT) in older adults presents challenges in patient selection and donor choice.
- Existing data on HCT for patients aged 50-69 are observational, highlighting the need for better health status assessment.
Purpose of the Study:
- To review current considerations for HCT in older adult patients.
- To evaluate the use of older sibling donors versus matched unrelated donors (MUDs).
- To discuss novel methods for assessing patient health status for transplantation candidacy.
Main Methods:
- Review of observational data on HCT outcomes in older adult populations.
- Analysis of comparative effectiveness between matched sibling donors and MUDs.
- Exploration of functional measures for health status assessment in elderly patients.
Main Results:
- Patients with excellent performance status and low comorbidity show the best long-term survival post-HCT.
- Older matched sibling donors yield equivalent or superior outcomes compared to MUDs.
- MUDs are a viable alternative, offering acceptable outcomes and disease control.
Conclusions:
- Novel health status measures can aid in selecting appropriate HCT candidates among older adults.
- Prioritizing older sibling donors is recommended, but MUDs and alternative donors can be considered.
- Further research is needed for HCT in patients and donors aged 70 and older.
Abstract:
Two lingering problems regarding transplantation in older adults have been how to select patients appropriately and whether to use older sibling donors. Allogeneic hematopoietic cell transplantation (HCT) of older patients may result in long-term survival due to GVL, but the data remain observational and mostly restricted to those 50 to 69 years of age. Patients with excellent performance status and low comorbidity have the best long-term survival after HCT. Novel measures of health status such as self-report or performance-based functional measures allow "staging the age" and may inform candidacy for less robust patients. Older matched sibling donors should be preferred over matched unrelated donors (MUDs) because outcomes are equivalent to superior for matched sibling donors compared with MUD. However, MUDs also achieve acceptable outcomes and long-term disease control. An alternative donor can be considered based on institutional protocols and expertise. Very limited information is available in patients or related donors 70 years of age and older. Future efforts to more completely characterize patient health status before transplantation will allow better application of HCT in older adults.
More Related Videos
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
07:08A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Related Concept Videos
Kidney Transplant I: Introduction
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Kidney Transplant II: Surgical Procedure
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Geriatric Patients